The Catholic University of Korea, Seoul St. Mary's Hospital
Welcome,         Profile    Billing    Logout  
 372 Trials 
1324 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, In K
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
NCT05439278: Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma

Not yet recruiting
3
268
NA
Hypofractionated radiotherapy, Conventional radiotherapy, Temozolomide
Seoul National University Boramae Hospital
Glioblastoma
07/25
07/27
NCT05253170: Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients

Not yet recruiting
3
622
NA
Hypofractionation, Conventional Fractionation
Seoul National University Bundang Hospital, Seoul National University Hospital
Breast Cancer, Radiotherapy; Complications
12/27
12/32
NCT05469022: Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy

Recruiting
2
40
RoW
Neoadjuvant lazertinib, Neoadjuvant LECLAZA
Konkuk University Medical Center, Yuhan Corporation
Non Small Cell Lung Cancer
05/24
05/27
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
NCT03558607: The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

Recruiting
1/2
17
RoW
Ruxolitinib
Seoul National University Hospital
Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder
04/22
08/24
NCT04122833: Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study

Recruiting
N/A
80
RoW
Next generation sequencing
Konkuk University Medical Center, Roche Diagnostics, Foundation Medicine
Adenocarcinoma of Lung, EGFR Activating Mutation
09/23
12/24
Sticherling, Michael
AMETHYST, NCT05531565 / 2020-000727-40: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
2
350
Europe, Canada, US, RoW
Eltrekibart, LY3041658, Placebo
Eli Lilly and Company
Hidradenitis Suppurativa
08/25
07/26
NCT04944862: A Study of CDX-0159 in Patients With Prurigo Nodularis

Hourglass Nov 2023 - Nov 2023 : Topline data from trial for prurigo nodularis
Completed
1
24
Europe, US
CDX-0159, barzolvolimab, Normal saline
Celldex Therapeutics
Prurigo Nodularis
07/23
07/23
Cloven, Noelle G
UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer

Terminated
3
20
Canada, US, RoW
Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo
Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
09/23
09/23
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
ENGOT en-21, NCT05797831: Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Recruiting
2/3
268
Europe, Canada, US, RoW
Navtemadlin, KRT-232, Navtemadlin Placebo
Kartos Therapeutics, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Endometrial Cancer
08/25
07/27
ZN-c3-004, NCT04814108: A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Recruiting
2
76
Canada, US, RoW
ZN-c3, azenosertib, KP-2638
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Uterine Serous Carcinoma
11/24
05/25
PROFECTA-II, NCT04374630: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed
2
150
US, RoW
Paclitaxel, Afuresertib, LAE002
Laekna Limited
Platinum-resistant Ovarian Cancer
07/23
06/24
PRESERVE-004, NCT05446298: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Active, not recruiting
2
58
US
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, MK3475, Keytruda
OncoC4, Inc., Merck Sharp & Dohme LLC, GOG Foundation
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
06/25
06/26
Uplift, NCT03319628 / 2020-000630-17: First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Active, not recruiting
1/2
523
US
upifitamab rilsodotin, XMT-1536, UpRi
Mersana Therapeutics
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
05/23
10/24
NCT05705505: Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

Recruiting
1/2
60
US
Narazaciclib, ON 123300, HX-301, Letrozole 2.5mg, Femara
Onconova Therapeutics, Inc.
Endometrioid Endometrial Cancer
01/26
02/26
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
Kim, Jae Weon
REMBRANDT, NCT04700436: Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia

Recruiting
4
240
RoW
Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg), Suvast tablet 10 mg (Rosuvastatin 10 mg)
Seoul National University Hospital, Gangnam Severance Hospital
Endocrine System Diseases, Nutritional and Metabolic Diseases, Diabetes Mellitus, Type 2, Dyslipidemias
05/21
11/21
NCT05662410: Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy

Not yet recruiting
4
30
NA
Three monthly injections of intravitreal aflibercept
Kim's Eye Hospital, Nune Eye Hospital, Seoul, Korea, HanGil Eye Hospital
Pachychoroid Neovasculopathy
06/23
12/23
NCT04655482: Treat-and-extend Using Aflibercept for Type 3 Neovascularization

Recruiting
4
30
RoW
Aflibercept Injection, Intravitreal injection of aflibercept (Eylea, Bayer co.)
Kim's Eye Hospital, Bayer
Retinal Angiomatous Proliferation
12/23
08/24
NCT06683950: Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment

Recruiting
4
40
RoW
Aflibercept 8mg
Kim's Eye Hospital
Age-related Macular Degeneration (ARMD)
12/25
05/26
NCT04840550: Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs

Recruiting
3
390
RoW
Lansoprazole 15 mg, Tegoprazan 25 mg
HK inno.N Corporation
Preventive Peptic Ulcer
06/24
07/24
RODIN, NCT05041010: Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz

Recruiting
3
496
RoW
Neu2000KWL group, Placebo group
GNT Pharma
Ischemic Stroke
06/24
01/25
DEBULK, NCT05421650: Therapeutic Effect of Surgical Debulking of Metastatic Lymph Nodes in Cervical Cancer Stage IIICr

Recruiting
3
234
RoW
CCRT, Surgical debulking of bulky or multiple lymph nodes
CHA University, Gachon University Gil Medical Center, Seoul St. Mary's Hospital, Korea University Ansan Hospital, National Cancer Center, Korea, Samsung Medical Center, Gangnam Severance Hospital, Asan Medical Center, Ewha Womans University, Hanyang University, DongGuk University, Seoul National University Hospital, Severance Hospital, Keimyung University Dongsan Medical Center, Kyungpook National University Chilgok Hospital, Pusan National University Yangsan Hospital, Korean Gynecologic Oncology Group
Cervical Cancer
03/26
03/29
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Recruiting
3
260
Europe, Canada, Japan, RoW
Carboplatin-Paclitaxel, Dostarlimab
ARCAGY/ GINECO GROUP, GlaxoSmithKline
Endometrial Cancer
04/26
10/29
EASTERN, NCT04214990: Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients

Recruiting
3
1700
RoW
Aspirin 100mg, Placebo oral tablet
National Cancer Center, Korea, Incheon St.Mary's Hospital/The Catholic University, Kosin University Gospel Hospital, Pusan National University Hospital, SMG-SNU Boramae Medical Center, Chonnam National University Hospital, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Chilgok Kyungpook National University, Hallym University Medical Center, Asan Medical Center, Seoul National University Bundang Hospital, Severance Hospital, Samsung Medical Center
Aspirin, Gastric Cancer
03/31
03/32
NCT03903211: Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease

Completed
2
84
RoW
[18F]PI-2620, FluoroTau
Jae Seung Kim
Cognitively Normal, Mild Cognitive Impairment, Alzheimer Disease
02/21
02/21
NCT04488094: Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation

Completed
2
7
RoW
[18F]FSPG, FSPG
Asan Medical Center
Graft Rejection, Heart Transplantation, Liver Transplantation
03/23
03/23
VISUALIZE, NCT06145048: Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

Recruiting
2
100
US, RoW
VGT-309
Vergent Bioscience, Inc.
Lung Cancer, Lung Metastases
11/24
12/24
RIC-NEC, NCT05279664: Randomized Controlled Trial

Recruiting
2
78
Canada, US
Remote ischemic conditioning (RIC) + Standard of Care for NEC, Standard of Care for NEC
The Hospital for Sick Children, Thrasher Research Fund, Mount Sinai Hospital, Canada, Sunnybrook Health Sciences Centre, McMaster Children's Hospital, Children's Hospital Medical Center, Cincinnati, Children's Hospital of Orange County, Karolinska University Hospital, Sophia Kindergeneeskunde, UCL Great Ormond Street Institute of Child Health, Hospital Universitario La Paz, University of Southampton
Necrotizing Enterocolitis
02/27
05/27
EB-203-201, NCT06487039: Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration

Recruiting
2
50
RoW
EB-203
EyebioKorea, Inc.
Neovascular Age-related Macular Degeneration (nAMD)
08/25
01/26
NCT06712615: Phase II Study of PG-102(MG12) Compared with Placebo in Obesity and Type 2 Diabetes

Recruiting
2
144
RoW
PG-102, Placebo
ProGen. Co., Ltd.
Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus
03/25
06/25
NCT05933031: Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients

Recruiting
2
381
RoW
Tegoprazan 50 mg Triple Therapy, Tegoprazan 100 mg Triple Therapy, Lansoprazole Triple Therapy
HK inno.N Corporation
Helicobacter Pylori Infection
12/24
12/24
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

Recruiting
2
150
Japan, US, RoW
KHK4951, Aflibercept Injection
Kyowa Kirin Co., Ltd.
Diabetic Macular Edema (DME)
11/25
12/25
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Recruiting
2
180
Japan, US, RoW
KHK4951, Aflibercept Injection
Kyowa Kirin Co., Ltd.
Neovascular Age-Related Macular Degeneration (nAMD)
11/25
12/25
TANGO, NCT06029595: Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy

Recruiting
2
464
Europe, RoW
Experimental: CHF6001 3200 μg, Placebo Comparator: CHF6001 Placebo
Chiesi Farmaceutici S.p.A.
Uncontrolled Asthma
12/25
12/25
NCT04156230: Diagnostic Validity of [18F]GP1 PET for Diagnosing Acute Deep Vein Thrombosis

Recruiting
2
63
RoW
[18F]GP1 positron emission tomography/computed tomography
Dae Hyuk Moon
Venous Thrombosis
12/25
12/25
NCT05509543: Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T

Completed
1
60
RoW
IY-NT-T, IY-NT-R, Noltec(the brand name)
Il-Yang Pharm. Co., Ltd.
Pharmacokinetics
10/22
12/23
NCT05729386: A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions

Recruiting
1
34
RoW
GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2), Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)
GC Biopharma Corp
Healthy Volunteers
04/23
04/23
NCT05703984: A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions

Recruiting
1
50
RoW
GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2), Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)
GC Biopharma Corp
Healthy Volunteers
04/23
04/23
NCT05617651: Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T

Not yet recruiting
1
50
RoW
IY-NT-T, IY-NT-R, Noltec(the brand name)
Il-Yang Pharm. Co., Ltd.
Pharmacokinetics
12/24
12/25
NCT01382420: Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma

Recruiting
N/A
234
RoW
surgery
Samsung Medical Center, Asan Medical Center, Severance Hospital, Konkuk University Medical Center
Cushing Syndrome
05/20
05/24
NCT05201846: Comparison of CSII and MDI in Pediatric Patients With Type 1 Diabetes

Recruiting
N/A
66
RoW
DIA:CONN G8 insulin pump, Multiple daily insulin injection
Seoul National University Hospital
Type 1 Diabetes
03/23
03/23
NCT05254652: The Clinical Effect of Pregabalin on Neuropathic Pain in Central Sensitized Patients After Total Knee Arthroplasty

Not yet recruiting
N/A
90
RoW
Duloxetine 30mg, Cymbalta 30mg, Pregabalin 150mg, Lyrica 150mg
The Catholic University of Korea
Osteoarthritis
05/23
05/23
NCT05322681: The Clinical Effect of Pregabalin on Neuropathic Pain in Non Central Sensitized Patients After Total Knee Arthroplasty

Not yet recruiting
N/A
90
RoW
Pregabalin 150mg, Lyrica 150mg
The Catholic University of Korea
Osteoarthritis
05/23
05/23
OFF-MAP, NCT03975179: Omitting vs. Doing Intraoperative Frozen Section Biopsy for Margin Status in Breast Conserving Surgery

Recruiting
N/A
1292
RoW
Omission of intraoperative frozen section biopsy for margin status, Frozen section biopsy for margin status
Samsung Medical Center, Korean Breast Cancer Study Group
Breast Cancer
06/23
06/26
NCT05525949: Visual Perceptual Learning Based Digital Therapeutics for Visual Field Defect After Stroke

Completed
N/A
93
RoW
VIVID Brain, No-treatment Control
Nunaps Inc
Visual Fields Hemianopsia, Hemianopsia, Homonymous
08/23
11/23
NCT05203627: Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery

Active, not recruiting
N/A
53
US
Best Practice, standard of care, standard therapy, Questionnaire Administration, Telemedicine Visit
City of Hope Medical Center, National Cancer Institute (NCI)
Gastric Carcinoma, Gastroesophageal Junction Adenocarcinoma
12/24
12/24
NCT03686007: Multimedia Self-Management Intervention for Lung Cancer Surgery Family Caregivers and Patients

Completed
N/A
355
US
Informational Intervention, Media Intervention, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Caregiver, Stage I Lung Cancer AJCC v7, Stage IA Lung Cancer AJCC v7, Stage IB Lung Cancer AJCC v7, Stage II Lung Cancer AJCC v7, Stage IIA Lung Cancer AJCC v7, Stage IIB Lung Cancer AJCC v7, Stage III Lung Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v7
08/24
08/24
NCT06406439: DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients

Recruiting
N/A
120
RoW
Smart Insulin Pen, DIA:CONN P8
G2e Co., Ltd
Diabetes Mellitus
10/24
12/24
KROG22-11, NCT05733156: Abscopal Effect from the Low-dose Radiotherapy in Polymetastatic Cancer Patients Receiving Stereotactic Radiotherapy

Recruiting
N/A
52
RoW
SBRT + LDRT
Soonchunhyang University Hospital, SMG-SNU Boramae Medical Center, Catholic University of Korea, St. Vincent Hospital, Seoul National University Hospital, Chungnam National University Hospital
Neoplasms, Secondary Malignant Neoplasm
12/25
06/26
ECLAT, NCT03438474: Endometrial Cancer Lymphadenectomy Trial

Recruiting
N/A
640
Europe, Japan, RoW
Standard surgical procedure for endometrial cancer, systematic lymphadenectomy (LNE)
Philipps University Marburg, German Cancer Aid
Cancer of Endometrium Stage I, Cancer of Endometrium Stage II
02/28
02/29
NCT05662943: Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

Completed
N/A
135
RoW
Intravitreal aflibercept injection
Kim's Eye Hospital
Polypoidal Choroidal Vasculopathy, Choroidal Neovascularization, Age-Related Macular Degeneration
05/23
11/23
Kim, Dong Soon
NCT06113198 / 2023-000764-58: A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

Recruiting
4
50
RoW
rMenB+OMV NZ
GlaxoSmithKline, GlaxoSmithKline Biologicals SA
Meningitis, Meningococcal
04/26
09/26
ODYSSEY, NCT04373564: Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Recruiting
4
2076
Europe, Canada, US, RoW
Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Eovist, Primovist, BAY86-4873, Gadobenate dimeglumine, MultiHance, Gadodiamide, Omniscan, Gadoterate meglumine, Dotarem, Magnescope, Gadobutrol, BAY86-4875, Gadavist, Gadovist, Gadoteridol, ProHance
Guerbet, Bayer AG (Sponsor), Bracco (Sponsor), GEHC (Sponsor)
Motor Function, Cognitive Function, Contrast Media
12/28
12/28
NCT01937806: Phase 3 and Extensional Study of Besifovir

Active, not recruiting
3
197
RoW
besifovir 150mg, tenofovir 300mg
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis B
02/16
01/23
Aladdin, NCT04618640: To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years

Recruiting
3
249
RoW
DTaP-IPV combination vaccine
Boryung Biopharma Co., Ltd.
Diphtheria, Tetanus, Pertussis, Poliomyelitis
12/20
07/21
NCT05051332: Phase 3 Clinical Trial of CartiLife® in Korea

Active, not recruiting
3
104
RoW
Autologous Chondrocyte Implantation (CartiLife®), CartiLife, Microfracture Surgery
Biosolution Co., Ltd.
Articular Cartilage Defect, Articular Cartilage Degeneration
09/23
09/24
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
NCT03459534: A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Recruiting
3
173
RoW
Radotinib HCl, SUPECT
Il-Yang Pharm. Co., Ltd.
Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory, CML - Philadelphia Chromosome
06/26
12/27
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting
3
693
Europe, Canada, Japan, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
08/25
04/26
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
NCT05733624: Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis

Completed
2
116
RoW
SCAI-001 0.01% eyedrop, Cyclosporine 0.01%, SCAI-001 0.02% eyedrop, Cyclosporine 0.02%, Restasis 0.05% eyedrop, Cyclosporine 0.05%
SCAI Therapeutics
Dry Eye Syndromes
08/23
02/24
EB-203-201, NCT06487039: Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration

Recruiting
2
50
RoW
EB-203
EyebioKorea, Inc.
Neovascular Age-related Macular Degeneration (nAMD)
08/25
01/26
GALAXIES LUNG-201, NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
340
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
10/25
10/28
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
NCT04775706 / 2021-000176-11: Phase 2 Study to Assess the Safety, PK, and PD in SBS-IF Subjects

Recruiting
2
18
Europe, US, RoW
HM15912 Active, Placebo
Hanmi Pharmaceutical Company Limited, Hanmi Pharm. Co., Ltd., Hanmi Pharmaceutical Co., Ltd.
Short Bowel Syndrome
12/27
05/28
NCT04446351: Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Recruiting
1
244
Canada, Japan, US, RoW
GSK6097608, Dostarlimab, Cobolimab, Belrestotug, GSK4428859A, EOS884448
GlaxoSmithKline, 23andMe, Inc., iTeos Therapeutics
Neoplasms
09/25
09/25
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

Active, not recruiting
1
16
Europe, Japan, US, RoW
Mezagitamab, TAK-079
Takeda
Kidney Disease, Glomerulonephritis
03/26
03/26
ELVN-001-101, NCT05304377: A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Recruiting
1
180
Europe, Canada, US, RoW
ELVN-001
Enliven Therapeutics
Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
12/26
12/26
MARS1, NCT04759794: Clinical Validation of an Immunocytochemistry Method Using

Recruiting
N/A
200
RoW
Cytology staining
Gangnam Severance Hospital
Bile Duct Obstruction, Extrahepatic
01/23
01/23
GLOBAL-AKI, NCT05387811: International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project

Completed
N/A
1456
Europe, US, RoW
Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy
Azienda Ospedaliera di Padova
Liver Cirrhosis, Acute Kidney Injury, Hepatorenal Syndrome
09/23
11/23
NCT05175053: Early RRT in AKI After Cardiac Surgery

Recruiting
N/A
202
RoW
Renal replacement therapy, Best medical management
Seoul National University Hospital, Seoul National University Bundang Hospital
Acute Kidney Injury
09/25
09/25
K-BIO, NCT03929887: KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis

Recruiting
N/A
3000
RoW
Kidney Biopsy
Seoul National University Hospital, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, KangWon National University Hospital, Keimyung University Dongsan Medical Center, SMG-SNU Boramae Medical Center, Seoul National University Bundang Hospital, Severance Hospital, Ministry of Health & Welfare, Korea
Glomerular Disease, Minimal Change Disease, IgA Nephropathy, Membranous Nephropathy, Focal Segmental Glomerulosclerosis, Lupus Nephritis, Crescentic Glomerulonephritis
12/28
12/28
Lee, Dong-Gun
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
12000
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Recruiting
3
274
Europe, US, RoW
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Ansun Biopharma, Inc.
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
08/25
08/25
FORMULA-OLS, NCT03583164 / 2017-001290-17: Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Completed
2
203
Europe, US, RoW
Olorofim, F901318
F2G Biotech GmbH, Iqvia Pty Ltd
Invasive Fungal Infections
02/23
02/23
Shahin, Mark
UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer

Terminated
3
20
Canada, US, RoW
Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo
Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
09/23
09/23
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
PROFECTA-II, NCT04374630: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed
2
150
US, RoW
Paclitaxel, Afuresertib, LAE002
Laekna Limited
Platinum-resistant Ovarian Cancer
07/23
06/24
GOG-3039, NCT04393285: Abemaciclib and Letrozole to Treat Endometrial Cancer

Active, not recruiting
2
53
US
Abemaciclib, Letrozole
Gynecologic Oncology Group, Eli Lilly and Company
Endometrial Cancer
12/24
12/25
GOG-3026, NCT03673124: Ribociclib and Letrozole Treatment in Ovarian Cancer

Active, not recruiting
2
51
US
Ribociclib, Letrozole
Gynecologic Oncology Group, Novartis
Low Grade Serous Carcinoma
12/23
12/24
NCI-2017-01672, NCT03660826: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Active, not recruiting
2
286
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Capivasertib, AZD 5363, AZD-5363, AZD5363, Truqap, Cediranib, AZ-D2171, AZD 2171, AZD2171, Cediranib Maleate, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI), NRG Oncology
Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Cancer AJCC v8
12/24
01/26
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
SOROCk, NCT04251052: A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Recruiting
N/A
2262
Canada, US, RoW
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, bilateral salpingo-oophorectomy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, transvaginal sonography, TVS, TVU, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
NRG Oncology, National Cancer Institute (NCI)
Ovarian Carcinoma
06/36
06/37
Investigator, Prinicpal
NCT05120895: An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia

Active, not recruiting
N/A
3300
RoW
Mevalotin
Daiichi Sankyo, Daiichi Sankyo Korea Co., Ltd.
Dyslipidemia
04/25
04/25
Kim, Inho
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
NCT03671850: VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients

Recruiting
2
48
RoW
VT-EBV-N, Placebo
ViGenCell Inc.
Extranodal NK/T-cell Lymphoma
12/23
06/24
NCT04189432: Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease

Active, not recruiting
2
84
RoW
SCM-CGH, Placebo
SCM Lifescience Co., LTD.
Chronic Graft-versus-host-disease
03/24
09/24
NCT06456463: A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Recruiting
2
76
US, RoW
Tagraxofusp, Tag, Venetoclax, Ven, Azacitidine, Aza
Stemline Therapeutics, Inc.
Acute Myeloid Leukemia
02/28
02/30
NCT04864418: AST-021p Study in Advanced Solid Tumors

Active, not recruiting
1
19
RoW
AST-021p
Aston Sci. Inc.
Advanced Cancer
08/23
11/23
NCT04840680: A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)

Completed
N/A
191
RoW
No Intervention
Takeda
Multiple Myeloma
07/23
08/23
Investigator, Principal
OCEAN, NCT04986982 / 2020-001175-32: OpiCapone Effect on Motor Fluctuations and pAiN

Completed
4
144
Europe
Opicapone 50 mg, BIA 9-1067, Placebo
Bial - Portela C S.A., Bial - Portela & Ca, S.A.
Parkinson Disease
02/24
02/24
 

Download Options